ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2022
Precision medicine versus standard of care for patients with myocardial infarction with non-obstructive coronary arteries (MINOCA): rationale and design of the multicentre, randomised PROMISE trial.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05122780. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PROgnostic Value of Precision Medicine in Patients With Myocardial Infarction and Non-obStructive Coronary artEries: the PROMISE Trial.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial.European heart journal · 2026Trial
- The Role of Serum Biomarkers for the Differential Diagnosis and Prognostic Assessment of Myocardial Infarction with Non-Obstructive Coronary Arteries: A Narrative Review.Journal of clinical medicine · 2026Review
- Intracoronary Imaging for the Management of Vulnerable Plaques.Journal of clinical medicine · 2026Review
- Device-Based Therapies for Refractory Angina.Journal of clinical medicine · 2025Review
- Ischemia with Non-Obstructive Coronary Artery Disease: Sex-Based Differences in Pathophysiology, Clinical Presentation, and Prognosis.Journal of clinical medicine · 2025Review
- Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features.Life (Basel, Switzerland) · 2025Review
- Angina Pectoris Prevalence and Sick Leave Burden 1 Year After Myocardial Infarction With Nonobstructive Coronary Arteries.Journal of the American Heart Association · 2025Article
- Antiplatelet Treatment Strategy in MINOCA Patients: Predictors of Decision Making in Clinical Practice and Prognostic Implications.Journal of clinical medicine · 2025Article
- Myocardial ischemia in nonobstructive coronary arteries: A review of diagnostic dilemmas, current perspectives, and emerging therapeutic innovations.World journal of cardiology · 2025Review
- The PROMISE of Precision Medicine in Myocardial Infarction with Non-Obstructive Coronary Arteries.Methods and protocols · 2025Review
- Sex-Related Differences in the Prognostic Role of Acetylcholine Provocation Testing.Journal of the American Heart Association · 2025Article
- Coronary microvascular dysfunction: pathophysiology, diagnosis, and therapeutic strategies across cardiovascular diseases.EXCLI journal · 2025Review
- Hypertensive Disorders of Pregnancy Increase the Risk for Myocardial Infarction: A Population-Based Study.Journal of the American College of Cardiology · 2024Article
- MINOCA: A Pathophysiological Approach of Diagnosis and Treatment-A Narrative Review.Biomedicines · 2024Review
- Precision Medicine in Acute Coronary Syndromes.Journal of clinical medicine · 2024Review
- Prognostic factors of MINOCA and their possible mechanisms.Preventive medicine reports · 2024Review
- Sex-specific and ethnicity-specific differences in MINOCA.Nature reviews. Cardiology · 2024Review
- Coronary Spasm Testing with Acetylcholine: A Powerful Tool for a Personalized Therapy of Coronary Vasomotor Disorders.Life (Basel, Switzerland) · 2024Review
- The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7.Cardiovascular diabetology · 2024Review
- MI and Non-obstructive Coronary Arteries.US cardiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction with non-obstructive coronary arteries (MINOCA) represents about 6-8% of patients presenting with myocardial infarction (MI), and it is associated with a significant risk of mortality, rehospitalisation, and angina burden, with high associated socioeconomic costs. It is important to note that multiple mechanisms may be responsible for MINOCA. However, to date, there are few prospective clinical trials on MINOCA and the treatment of these patients is still not defined, most likely because of the multiple underlying pathogenic mechanisms. The PROMISE trial is a randomised, multicentre, prospective, superiority, phase IV trial that will include 180 MINOCA patients randomised 1:1 to a "precision-medicine approach", consisting of a comprehensive diagnostic workup and pharmacological treatment specific for the underlying cause, versus a "standard of care" approach, consisting of routine diagnostic workup and standard medical treatment for acute coronary syndrome. The aim of this study is to evaluate if the "precision-medicine approach" will improve the angina status, evaluated using the Seattle Angina Questionnaire summary score, at 12 months (primary endpoint). Secondary endpoints include the rate of major adverse cardiovascular events at 12-month follow-up, the related primary and secondary healthcare costs, and the ability of cardiac magnetic resonance to evaluate the different mechanisms of MINOCA. Of importance, the results derived from this trial may pave the way for a new pathophysiology-driven approach with cause-target therapies personalised for the mechanisms of MINOCA (ClinicalTrials.gov: NCT05122780).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.